Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by ...

Novo Nordisk will cover the costs of early development and clinical testing. It’s also responsible for regulatory, commercial manufacturing, and commercialization of products stemming from the ...

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity ...

Novo Nordisk said it expects continued capacity limitations at some manufacturing sites. It revised full-year sales growth guidance to a range of 23% to 27% from 22% to 28%. American depositary ...